High concordance of TMPRSS-ERG fusion between primary prostate cancer and its lymph node metastases
暂无分享,去创建一个
T. Schlomm | S. Steurer | C. Wittmer | R. Simon | F. Jacobsen | W. Wilczak | S. Minner | M. Tsourlakis | H. Heinzer | M. Graefen | H. Huland | M. Kluth | C. Hube-Magg | A. Hinsch | K. Grupp | P. Lebok | D. Lang | F. Brandi | Christina M�ller‑Koop
[1] N. Muhammad,et al. Cancers , 2018, Examining the Causal Relationship Between Genes, Epigenetics, and Human Health.
[2] S. Varambally,et al. Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. , 2017, Cancer cell.
[3] J. Korbel,et al. Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients , 2016, BMC Cancer.
[4] P. Couvreur,et al. Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide , 2016, Molecular therapy. Nucleic acids.
[5] S. Serrano,et al. Association of ERG and TMPRSS2‐ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels , 2015, The Prostate.
[6] P. Couvreur,et al. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer , 2015, PloS one.
[7] S. Terry,et al. Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer , 2015, Cancer.
[8] T. Visakorpi,et al. Prevalence and prognostic significance of TMPRSS2‐ERG gene fusion in lymph node positive prostate cancers , 2014, The Prostate.
[9] J. Oxley,et al. Quantitative analysis of ERG expression and its splice isoforms in formalin-fixed, paraffin-embedded prostate cancer samples: association with seminal vesicle invasion and biochemical recurrence. , 2014, American journal of clinical pathology.
[10] J. Suh,et al. Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer. , 2014, International journal of clinical and experimental pathology.
[11] P. Stattin,et al. TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers , 2014, PloS one.
[12] A. Sood,et al. Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene Using Liposomal Nanovectors , 2012, Clinical Cancer Research.
[13] B. Czerniak,et al. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. , 2012, Human pathology.
[14] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[15] G. Nesi,et al. Clinical importance of lymph node density in predicting outcome of prostate cancer patients. , 2011, The Journal of surgical research.
[16] B. Wiese,et al. Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down‐regulated in matched lymph node metastases , 2011, The Prostate.
[17] C. Magi-Galluzzi,et al. Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Rubin,et al. Testing mutual exclusivity of ETS rearranged prostate cancer , 2010, Laboratory Investigation.
[19] F. Deng,et al. Detection of TMPRSS2 Gene Deletions and Translocations in Carcinoma, Intraepithelial Neoplasia, and Normal Epithelium of the Prostate by Direct Fluorescence In Situ Hybridization , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[20] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[21] M. Rubin,et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. , 2010, Urology.
[22] M. Rubin,et al. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. , 2007, Urology.
[23] S. Dhanasekaran,et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer , 2007, Nature.
[24] Debashis Ghosh,et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.
[25] F. Wawroschek,et al. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. , 2007, The Journal of urology.
[26] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[27] B. Wullich,et al. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. , 2004, The Journal of urology.
[28] F. Burkhard,et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? , 2003, The Journal of urology.
[29] T. Stamey,et al. Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.
[30] K. Klose,et al. [Venous occlusive disease of the liver--a rare pregnancy complication]. , 1990, Der Internist.
[31] P. Scardino,et al. Prognostic significance of lymph nodal metastases in prostate cancer. , 1989, The Journal of urology.
[32] G. Sauter,et al. Marked heterogeneity of ERG expression in large primary prostate cancers , 2013, Modern Pathology.
[33] S. Dhanasekaran,et al. ETS rearrangements and prostate cancer initiation , 2009, Nature.
[34] D. Bostwick,et al. Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.
[35] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.